Organization
Tenon Hospital IUC-UPMC
3 abstracts
Abstract
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Universidad Europea de Madrid,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
BIOLOGICS AND JAK INHIBITORS EFFICACY IN VEXAS SYNDROME FROM FRENCH MULTICENTER CASE SERIES OF 256 PATIENTSOrg: Saint Antoine Hospital, Tunis CHU, Internal Medicine, Tunis, Tunisia, Cochin and Hôtel-Dieu Hospitals, Toulouse, Sainloiueoi,